NanoSyrinx Ltd.
June 16, 2025
Company Presentation
Platform for Therapeutics
NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein Nanosyringes as a next-generation platform technology for the targeted intracellular delivery of biological molecules.
Our vision at NanoSyrinx is to unlock the interior of the cell and the myriad therapeutic opportunities within that are currently difficult (or impossible) to drug, by enabling targeted, intracellular delivery of protein therapeutics.
NanoSyrinx closed a £10m financing round in August 2024, led by BGF (London), M Ventures (Amsterdam) and Octopus Ventures (London) and supported by Eli Lilly and Company, IQ Capital (Cambridge) and Jonathan Milner (Cambridge).
Company HQ City:
Coventry
Company HQ State:
England
Company HQ Country:
United Kingdom
Year Founded:
2020
Lead Product in Development:
Undisclosed
CEO
Dr Joseph Healey
Year Founded
2020
Development Phase of Lead Product
Discovery
What is your next catalyst (value inflection) update?
2025-Q2
Website
https://www.nanosyrinx.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}